This common molecule could reverse muscle ageing and prevent frailty, scientists say
A common molecule found in the body could be targeted to turn aged muscle cells to become young again, helping prevent frailty in older people, a new study suggests.
The populations of developed countries are getting older, leading to higher rates of associated frailty and debilitation among their people.
Gradual muscle loss in these populations is accelerated by the poor capacity of muscle tissues in older people to repair injury, especially after falls or surgeries.
This leads to a condition called sarcopenia, or low muscle mass, in older people, making them prone to even more frailty and movement problems.
Previous studies have shown that muscle stem cells play a key role in repairing such tissue damage, but they become dysfunctional with age.
Researchers have been trying to understand how aged stem cells differ from young ones and to find ways to reverse these changes.
A new study, published in the journal Cell Stem Cell, reveals that aged mice treated with a naturally occurring molecule in the body called Prostaglandin E2 (PGE2) show improved regeneration and strength of aged muscle.
Scientists also found that the PGE2 molecule works by counteracting stem cell ageing.
In the study, researchers examined the effects of PGE2 and its related molecule EP4 on the body.
Previous research has shown that during muscle injury, PGE2 triggers muscle stem cells to regenerate the muscles of young mice.
In aged mice, scientists found that the EP4 production in muscle stem cells was either lacking, or reduced by half compared to levels found in young stem cells.
'PGE2 is an alarm clock to wake up the stem cells and repair the damage. Aging essentially reduces the volume of the alarm and the stem cells have also put on ear plugs,' said study author Yu Xin Wang.
The new research has found a way to reset the intensity of this cellular alarm clock.
When scientists gave a stable form of PGE2 to aged mice after muscle injury and in conjunction with exercise, they found that the treated mice gained more muscle mass and were stronger compared to untreated ones.
'What amazes me most is that a single dose of treatment is sufficient to restore muscle stem cell function, and that the benefit lasts far beyond the duration of the drug,' Dr Wang said.
'In addition to making new muscle, the stem cells stay in the tissue, where they sustain the effect of the PGE2 and instil the muscle with further capacity to regenerate,' he said.
The study found that PGE2 treatment can restore stem cell function and reverse many of the age-related changes in mice muscles.
'PGE2 has been implicated in the regenerative process and signalling for the intestine, liver, and several other tissues, potentially opening up an approach that could restore the renewing capacity of other aged tissues,' Dr Wang said.
'We have discovered that the PGE2 induces rejuvenation of aged muscle stem cells, which leads to functional improvements in muscle repair and strength,' scientists concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
23 minutes ago
- Daily Mail
Weight loss jabs like Mounjaro now linked to more than a HUNDRED deaths, the UK's drug watchdog confirms
Slimming jabs like Mounjaro and Wegovy have been linked to more than 100 deaths in Britain, it was revealed today. None of the fatalities, which have all been reported since the jabs were licensed for use in the UK, are proven to have been caused directly by the drugs. However, health chiefs tasked with policing the safety of medicines admit reports of side effects indicate 'a suspicion' they may have been to blame. A total of 111 deaths were logged with the regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), up to and including May 29. These are based on patients' families or healthcare workers informing the MHRA of a suspected fatal reaction to the drugs, known as glucagon-like peptide-1 receptor agonists (GLP-1RAs). It comes just months after the death Scottish nurse Susan McGowan, 58, who experienced multiple organ failure, septic shock and pancreatitis after taking just two doses of Mounjaro. Hers is the only confirmed fatality linked to the jabs in the UK. But it comes at a time when ministers are planning to rollout the jabs—described as game changers in the fight against obesity— to even more Britons. The deaths may also be caused by underlying medical conditions or other medications taken at the same time and therefore can be coincidental the MHRA told trade magazine Chemist+Druggist. Officials use the MHRA's 'Yellow Card' database, set-up in the wake of the 1960s thalidomide scandal, to track the safety of medications currently in use in Britain. Although almost impossible to prove, the system allows doctors, pharmacists and patients to report adverse reactions they believe are linked to medications and allows officials to uncover potential patterns. The weight-loss medication linked to the most deaths, in the system was liraglutide—sold under the brand name Saxenda—with 37 reports of a fatal outcome. In second place was tirzepatide—sold as Mounjaro and once hailed the 'King Kong' of slimming jabs—with 33 deaths. And in third place was semaglutide—the active ingredient in the weight loss jab Wegovy as well diabetes drug Ozempic—which was linked to 30 deaths. A further seven reports were liked to dulaglutide—known as Trulicity—and five to lixisenatide—which has the trade name Lyxumia. Of the total fatal reports, 32 involved jabs indicated for 'weight management alone or 'only licensed for weight management—Mounjaro, Saxenda, Wegovy'. Meanwhile, 40 reports related to drugs with an indication for 'diabetes alone'. Another nine referred to patients getting the jab for 'both weight management or diabetes'. While 30 reported a fatal outcome 'with an indication other than weight management or diabetes, or where no indication has been reported', the watchdog told Chemist+Druggist. Last year, medics warned they were seeing a wave of patients of healthy weight taking the drugs in a bid to become 'beach-body ready'. Such patients, mostly young women, were landing in A&E after obtaining the drugs online under false pretences. Currently, patients can obtain the drugs from many chemists by filling in online forms with details of their weight and height and submitting photographs of themselves. However, experts and organisations such as the Society for Acute Medicine have called for tighter restrictions on how Ozempic, Mounjaro and other weight-loss products are prescribed. A spokesperson for Lilly UK, the makers of Mounjaro, said patient safety is its 'top priority'. It added: 'Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.' 'If anyone is experiencing side effects when taking any Lilly medicine, they should talk to their doctor or other healthcare professional.' There has been growing concern after reports of side effects from the drugs. These include including nausea, vomiting, diarrhoea, bone fractures, tooth damage, severe anxiety and depression. Earlier this month, women reported terrifying mental health side effects after using Mounjaro. The jab, along with similar treatments such as Ozempic and Wegovy, can help patients lose up to 15 per cent of their body weight in a year.
Daily Mail
37 minutes ago
- Daily Mail
The four US states where psychopaths are most likely to live... are YOU living near one?
Scientists have uncovered the US states where people are more likely to have 'dark' traits. Researchers measured four traits — narcissism, Machiavellianism, psychopathy and sadism — across all 50 states, using data from at least 100 participants in each. Nevada, Louisiana, New York and Texas scored among the highest when it came to these devious characteristics. The study suggested that higher levels of dark traits in certain areas may be influenced by unfavorable societal conditions, such as poverty, crime, inequality, and scarcity of resources, which can foster dark traits. Nevada scored the highest likely due to its gambling culture linked to risky behavior, while South Dakota suffers from high poverty and inequality, poor health care and limited resources. New York and Texas experience stark economic inequality, with extreme wealth right next to poverty, which may have attributed to the high score. However, Vermont, Massachusetts, New York and Maine are among the states that scored the lowest in dark traits. These states typically enjoy more favorable societal conditions, such as higher education and income, better healthcare and strong social services. The study was conducted by researchers at the University of Copenhagen in Denmark, who asked thousands of people to answer a survey via their own website. The data of 144,576 Americans was collected from February 2, 2019 to February 19, 2024. To measure aversive societal conditions (ASC), the team creator an indicator based on corruption, inequality, poverty and violence. They used Census Bureau data on inequality and poverty, homicide rates and Justice Department corruption convictions, Newsweek reported. Other states that scored high included Louisiana, Alabama and Mississippi, states with high crime rates, poverty and worse access healthcare. California also made the list as it has some of the widest income gaps in the country, especially in major urban areas like Los Angeles and San Francisco, where wealthy tech and entertainment sectors coexist with large populations facing poverty and homelessness. Certain areas in California also struggle with higher crime rates, gang activity and drug-related issues, which may contribute to increased suspicion, aggression or defensive behaviors among residents. The team found a small but significant link between a state's ASC score and the average Dark Factor of Personality (D) score of its people. The study suggested that higher levels of dark traits in certain areas may be influenced by unfavorable societal conditions, such as poverty, crime , inequality, and scarcity of resources, which can foster dark traits Alaska, Oregon and much of the Rocky Mountain states scored the opposite. Experts have suggested that the lower D scores in Alaska, Oregon, and many Rocky Mountain states can be attributed to a confluence of geographical isolation, cultural heritage emphasizing individualism and resilience and social environments that promote cooperation and adaptability. This pattern remained nearly the same after we controlled for age and gender, researchers said. The team also found that the conditions in US state, measured by the ASC index, are related to people's aversive personalities about 20 years later. This supports the idea that a society's environment can help shape a person's traits and adds to what is known about how aversive personalities develop. 'This is to be expected as both genetic and other socioecological factors likely also affect individuals' aversive personality,' researchers shared in the study published in . Proceedings of the National Academy of Sciences. 'Moreover, even relatively small effects can be cumulative in nature, so the relation between ASC and D may have important consequences at scale, especially because higher aversive personality levels imply notable costs for others and/or society.' Professor Ingo Zettler told Newsweek that he and his team were curious if 'adverse societal conditions contribute to the proliferation of selfish, egoistic and other traits.' 'Aversive personality traits are associated with behaviors such as aggression, cheating and exploitation, and thus with high social costs,' he added. 'Therefore, even small variations can lead to large differences in how societies function.'
The Independent
3 hours ago
- The Independent
Breakthrough blood test detects cancer years before symptoms appear
Scientists have developed a 'highly sensitive' blood test that could detect signs of cancerous tumours years before the first symptoms appear, an advance that could lead to better treatment outcomes for patients. Researchers from the Johns Hopkins University in the US found that genetic material shed by tumours can be detected in the bloodstream much before patients get their first diagnosis. The study, published in the journal Cancer Discovery, found that these genetic mutations caused by cancer, can be detected in the blood over three years in advance for some patients. 'Three years earlier provides time for intervention. The tumours are likely to be much less advanced and more likely to be curable,' said study co-author Yuxuan Wang. In the research, scientists assessed blood plasma samples collected from participants of a large NIH-funded study to investigate risk factors for heart attack, stroke, heart failure and other cardiovascular diseases. Researchers developed highly accurate and sensitive genome sequencing techniques to analyse blood samples from 52 of the earlier study's participants. Twenty-six of the participants were diagnosed with cancer within six months after sample collection, and 26 who were not diagnosed served as the control group for comparison. Eight of the 52 participants scored positively in a multicancer early detection (MCED) laboratory test conducted at the time their blood samples were taken. The MCED test is designed to detect multiple cancers in their early stages from a single blood sample by analysing cancer-signature molecules in the blood, including DNA and proteins. All eight were diagnosed with cancer within four months following blood collection. For six of these 8 participants, additional blood samples were collected about 3 to 3.5 years before cancer diagnosis. In four of these cases, mutations linked to tumour growth could be identified in their earlier blood samples. The findings point to 'the promise of MCED tests in detecting cancers very early', researchers say. It may lead to more standardised blood tests to screen people either annually or every two years, which could boost early detection and prevent cancers from becoming treatment-resistant tumours. 'These results demonstrate that it is possible to detect circulating tumour DNA more than three years prior to clinical diagnosis, and provide benchmark sensitivities required for this purpose,' scientists wrote. 'Detecting cancers years before their clinical diagnosis could help provide management with a more favourable outcome,' said Nickolas Papadopoulos, another author of the study. Scientists hope the findings can be validated in a larger-scale trial involving more participants.
